Budget impact analysis of medicines: updated systematic review and implications
DR Faleiros, J Álvares, AM Almeida… - Expert review of …, 2016 - Taylor & Francis
This evaluation determines whether published studies to date meet the key characteristics
identified for budget impact analyses (BIA) for medicines, accomplished through a …
identified for budget impact analyses (BIA) for medicines, accomplished through a …
[HTML][HTML] A methodological review of US budget-impact models for new drugs
J Mauskopf, S Earnshaw - Pharmacoeconomics, 2016 - Springer
A budget-impact analysis is required by many jurisdictions when adding a new drug to the
formulary. However, previous reviews have indicated that adherence to methodological …
formulary. However, previous reviews have indicated that adherence to methodological …
Cost-effectiveness of surgery, stereotactic body radiation therapy, and systemic therapy for pulmonary oligometastases
NH Lester-Coll, CE Rutter, TJ Bledsoe… - International Journal of …, 2016 - Elsevier
Introduction Pulmonary oligometastases have conventionally been managed with surgery
and/or systemic therapy. However, given concerns about the high cost of systemic therapy …
and/or systemic therapy. However, given concerns about the high cost of systemic therapy …
晚期非小细胞肺癌基本证型探讨
龚亚斌， 王中奇， 赵晓珍， 邓海滨， 苏婉， 王立芳… - 上海中医药大学 …, 2012 - cqvip.com
目的: 探讨晚期非小细胞肺癌(non-small cell lung cancer, NSCLC) 的基本中医证型. 方法:
纳入晚期NSCLC 患者338 例, 收集患者的临床症状, 应用因子分析方法对症状进行分类 …
纳入晚期NSCLC 患者338 例, 收集患者的临床症状, 应用因子分析方法对症状进行分类 …
[HTML][HTML] A systematic review of the budget impact analyses for antitumor drugs of lung cancer
L Han, X Zhang, WQ Fu, CY Sun, XM Zhao… - Cost Effectiveness and …, 2020 - Springer
Abstract Background Budget impact analyses (BIAs) are used for reimbursement decisions
and drug access medical insurance, as a supplement to cost-effectiveness analyses (CEAs) …
and drug access medical insurance, as a supplement to cost-effectiveness analyses (CEAs) …
A review of economic impact of targeted oral anticancer medications
C Shen, CR Chien, DM Geynisman… - Expert review of …, 2014 - Taylor & Francis
There has been a rapid increase in the use of targeted oral anticancer medications (OAMs)
in the past decade. As OAMs are often expensive, economic consideration play a significant …
in the past decade. As OAMs are often expensive, economic consideration play a significant …
Budget impact of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US commercial payer …
D Stellato, ME Gerbasi, B Ndife, SR Ghate… - Journal of Managed …, 2019 - jmcp.org
BACKGROUND: Before the approval of dabrafenib and trametinib in combination, there
were no approved therapies in the adjuvant setting that target the RAS/RAF/MEK/ERK …
were no approved therapies in the adjuvant setting that target the RAS/RAF/MEK/ERK …
Clinical and economic review of erlotinib in non-small-cell lung cancer
K Yeung, JJ Carlson - Expert review of pharmacoeconomics & …, 2012 - Taylor & Francis
Lung cancer has the highest incidence and mortality among cancers of both men and
women. Treatment strategies for non-small-cell lung cancer, the most common form of lung …
women. Treatment strategies for non-small-cell lung cancer, the most common form of lung …
The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non–small cell lung cancer harboring epidermal growth factor receptor exon …
L Hernandez, M Young - Journal of Managed Care & Specialty Pharmacy, 2023 - jmcp.org
BACKGROUND: Lung cancer is a leading cause of cancer morbidity and death in the United
States. Non–small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases, and …
States. Non–small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases, and …
清热解毒活血化瘀法治疗川崎病30 例临床观察
肖蓉， 马新蕾 - 长春中医药大学学报, 2013 - cqvip.com
目的: 观察清热解毒, 活血化瘀法治疗川崎病的临床疗效. 方法: 将30 例川崎病患儿随机分为2 组,
对照组确诊后立即给予大剂量丙种球蛋白静滴, 阿司匹林, 潘生丁等药物口服; …
对照组确诊后立即给予大剂量丙种球蛋白静滴, 阿司匹林, 潘生丁等药物口服; …